The Weekly Roundup: January 12-16

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Q&A: Adelle Walker on How Functional Wellness is Redefining Aesthetic Dermatology in 2026

Adelle Walker explores the future of aesthetics as personalized, holistic approaches and regenerative treatments, particularly in younger patients, reshape trends in 2026.

Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

The Impact of Skin Tension Line Orientation in Full-Thickness Skin Grafting for BCC

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis

Dupilumab shows significant effectiveness and safety in treating severe AD in children aged 6 months to 5 years, enhancing quality of life.

Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors

Zasocitinib emerges as a highly selective and potent allosteric TYK2 inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT

Alpha Tau advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma, offering a novel, localized treatment option with minimal toxicity.

Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Insights from the Multinational RWEAL Study on CHE Etiology, Severity, and Real-World Management

The RWEAL study uncovers real-world management of chronic hand eczema, highlighting treatment gaps and the need for standardized assessment in clinical practice.

Journal Digest: January 14, 2026

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

NPF Position Statement Aligns Severity Classification With Treatment Needs

The NPF redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

Utilizing CYP2C9 Testing and JAK Inhibitors for Alopecia Areata

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

Timing, Severity, and Therapeutic Choice in Moderate to Severe HS

Explore the complexities of managing HS through real-world case studies moderated by Afsaneh Alavi, MD.

Off-Label Case Series: Topical Roflumilast for Mild HS

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Auricular Acupuncture for Facial Rejuvenation: Results from a Large Real-World Clinical Series

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

New Research Evaluates Ablative CO₂ Laser Therapy for Refractory Hailey–Hailey Disease

Researchers explore CO₂ laser therapy's effectiveness for refractory HHD, revealing its potential to restore skin health and reduce inflammation.

Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib

Heap discusses promising phase 3 results for zasocitinib, an oral TYK2 inhibitor, showcasing its efficacy and safety in psoriasis therapy.

Reliability of AI Tools for Post-Mohs Patient Guidance

A recent study evaluated how accurately, appropriately, and completely several commonly used large language models respond to typical postoperative concerns.

Lebrikizumab Enters Late-Stage Testing for Nummular Eczema

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Sun Pharma’s Cosibelimab-ipdl (UNLOXCYT) Enters US Market for Advanced CSCC

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Derm Dispatch: Navigating the Ethics of AI-Assisted Dermatology

Renata Block, DMSc, MMS, PA-C, explores how AI could transform dermatology with insights from Dr. GPT on integration, equity, and the future of patient care.

Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis.